Short Interest in Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Rises By 284.5%
by Doug Wharley · The Cerbat GemValion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 245,772 shares, an increase of 284.5% from the April 15th total of 63,926 shares. Currently, 8.0% of the company’s shares are short sold. Based on an average daily trading volume, of 325,146 shares, the days-to-cover ratio is presently 0.8 days.
Valion Bio, Inc. Common Stock Trading Down 12.0%
Shares of NASDAQ VBIO traded down $0.13 during midday trading on Wednesday, reaching $0.97. 147,224 shares of the stock were exchanged, compared to its average volume of 239,030. The company has a market capitalization of $3.04 million, a P/E ratio of -0.14 and a beta of 1.86. Valion Bio, Inc. Common Stock has a 52-week low of $0.72 and a 52-week high of $5.60. The company has a current ratio of 20.13, a quick ratio of 20.13 and a debt-to-equity ratio of 0.38. The stock has a 50 day moving average price of $1.01 and a 200-day moving average price of $1.40.
Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($408.00) by $406.97.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
View Our Latest Research Report on VBIO
Valion Bio, Inc. Common Stock Company Profile
Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.
The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.